Sentante’s Endovascular Robot Enters Commercial Use in Vascular Surgery

Sentante has begun commercial deployment of its CE-marked endovascular robotic platform, the medical robotics company announced on August 20, 2026, with vascular surgery and interventional radiology as its first clinical markets. The move takes the Kaunas-based company from regulatory clearance into revenue-generating clinical use three months after its CE mark, granted in May 2026. The announcement frames the commercial rollout as the start of the company's physical AI strategy: every…

This article has been indexed from Unite.AI

Read the original article: